Abstract
Interleukin-4 (IL-4)-induced Stat6 activities (phenotypes) vary among human cancer cells, of which the HT-29 cell line carries an active Stat6(high) phenotype, while Caco-2 carries a defective Stat6(null) phenotype, respectively. Cancer cells with Stat6(high) show resistance to apoptosis and exaggerated metastasis, suggesting the clinical significance of Stat6 phenotypes. We previously showed that Stat6(high) HT-29 cells exhibited low constitutive expression of Stat6-negative regulators SOCS-1 and SHP-1 because of gene hypermethylation. This study further examined the constitutive expression of other closely related SOCS family numbers including SOCS-3, SOCS-5, SOCS-7, and CISH using RT-PCR. Similar to SOCS-1 and SHP-1, Stat6(high) HT-29 cells expressed low constitutive mRNA of SOCS-3, SOCS-7, and CISH than Stat6(null) Caco-2 cells. Interestingly, DNA demethylation using 5-aza-2'-deoxycytidine in HT-29 cells up-regulated mRNA expression of the above genes, indicating a hypermethylation status, which was confirmed by methylation-specific sequencing in selected SOCS-3 gene. Furthermore, defective Stat6(null) Caco-2 exhibited impaired phosphorylation of Stat6 after IL-4 stimulation by flow cytometry, in keeping with the notion of ...Continue Reading
References
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Jun 8, 1999·Annual Review of Immunology·K NelmsW E Paul
Aug 24, 1999·Molecular and Cellular Biology·A MatsumotoA Yoshimura
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·S E NicholsonM Baca
Aug 22, 2000·The Journal of Biological Chemistry·S J HaqueB R Williams
Nov 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S Ostrand-RosenbergV K Clements
Nov 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·A K KachaT F Gajewski
Jun 27, 2002·British Journal of Cancer·S I BaeW H Kim
Mar 26, 2003·Human Immunology·Wen Jie ZhangMichael J Chorney
Apr 5, 2003·Protein Engineering·Fabrizio Giordanetto, Romano T Kroemer
Sep 25, 2003·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Peter O Krutzik, Garry P Nolan
Nov 1, 2003·Cancer Immunology, Immunotherapy : CII·Suzanne Ostrand-RosenbergErika Danna
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Nov 4, 2004·The Journal of Surgical Research·Eva GalkaWalter A Koltun
Jan 29, 2005·The Journal of Biological Chemistry·Nele MartensArieh Gertler
Jul 12, 2005·Oncogene·Anette WeberAndrea Tannapfel
Oct 11, 2005·Critical Reviews in Oncology/hematology·Heather A Bruns, Mark H Kaplan
Dec 13, 2005·Nature Clinical Practice. Oncology·Stephen B Baylin
Jan 3, 2006·Cancer Letters·Mingsheng ZhangWen Jie Zhang
Mar 17, 2006·Cytokine & Growth Factor Reviews·Daniel HebenstreitAlbert Duschl
Mar 23, 2006·Annual Review of Immunology·K Mark AnselAnjana Rao
Jan 3, 2007·Developmental Biology·Yoko OzawaHideyuki Okano
Feb 26, 2008·Biochemical and Biophysical Research Communications·Ben Hui LiWen Jie Zhang
Mar 18, 2008·Cytokine·Wen Jie ZhangMichael J Chorney
Jun 10, 2008·Journal of Cancer Research and Clinical Oncology·Qin YuanWen Jie Zhang
Aug 19, 2008·Seminars in Cell & Developmental Biology·Ben A CrokerSandra E Nicholson
Oct 25, 2008·Cytokine & Growth Factor Reviews·Julie PiessevauxJan Tavernier
Apr 7, 2009·Indian Journal of Cancer·S B Omay, M A Vogelbaum
Citations
Nov 15, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Sungpil YoonSuk Woo Nam
Oct 11, 2012·Genetic Testing and Molecular Biomarkers·Mehri IgciA Tuncay Demiryurek
Apr 24, 2014·Molecular Biology International·Walid SasiKefah Mokbel
Aug 15, 2013·Journal of Viral Hepatitis·X ZhangF Lu
Nov 24, 2011·Cellular Signalling·Ben Hui LiWen Jie Zhang
May 17, 2019·Cancers·Rudy MevizouSerge Roche
Aug 28, 2021·Cancers·Esra'a Keewan, Ksenia Matlawska-Wasowska